HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BAY 14-2222

a recombinant FVIII formulated with sucrose

Also Known As:

BAY-14-2222; BAY14-2222

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fukutake, K: 1 article (07/2000)
2.	Shima, M: 1 article (07/2000)
3.	Shirahata, A: 1 article (07/2000)
4.	Takamatsu, J: 1 article (07/2000)
5.	Yoshioka, A: 1 article (07/2000)

Related Diseases

1.	Hemorrhage 07/01/2000 - "In addition, it was shown that BAY 14-2222 is effective in preventing bleeding. " 07/01/2000 - "Results indicated that BAY 14-2222 has a good preventive effect on bleeding. " 07/01/2000 - "In stage II, BAY 14-2222 was administered regularly to the 5 patients with hemophilia at single doses of 20 to 40 IU/kg 3 times weekly for 4 weeks, and its prophylactic effect on bleeding was evaluated. "
2.	Hemophilia A (Haemophilia) 07/01/2000 - "In stage II, BAY 14-2222 was administered regularly to the 5 patients with hemophilia at single doses of 20 to 40 IU/kg 3 times weekly for 4 weeks, and its prophylactic effect on bleeding was evaluated. " 07/01/2000 - "Thus it is expected that BAY 14-2222 will exhibit a hemostatic effect comparable to that of Kogenate in patients with hemophilia A." 07/01/2000 - "A clinical trial of BAY 14-2222, a recombinant factor VIII preparation (rFVIII) manufactured by new purification and formulation processes using sucrose as a stabilizer instead of human serum albumin, was performed in 5 previously treated Japanese patients with severe hemophilia A. "

Related Drugs and Biologics

1.	Sucrose (Saccharose)
2.	Hemostatics (Antihemorrhagics)
3.	Factor VIII (Coagulation Factor VIII)
4.	Human Serum Albumin
5.	human F8 protein